Project Grant HT94252510866
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is focused on "REVERSIBILITY AND THERAPEUTIC TARGETING OF TREATMENT- EMERGENT NEUROENDOCRINE PROSTATE CANCER" and will be performed by the Dana-Farber Cancer Institute, Inc. (Dfci) located in Boston, MA. The grant supports advanced biomedical research aimed at transforming healthcare for military service members,...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
The Defense Health Agency awarded a $1,290,499.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on conducting research to develop innovative approaches to understanding, detecting, and treating ovarian cancer. DFCI, a prestigious non-profit cancer research center, will...
The federal Project Grant award in the amount of $178,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding research at the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts to target the Merkel ST-MYCL-EP400 complex in Merkel cell carcinoma. The research aims to develop innovative approaches to the understanding, detection, and treatment of this rare and aggressive form of skin cancer...
This federal Project Grant award, totaling $4,991,950.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is funding the "INVESTIGATION OF A MULTICANCER EARLY DETECTION TEST IN A HIGH-RISK MILITARY POPULATION" at the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project aims to develop and evaluate a novel multicancer early detection test for use within a high-risk military...
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...
This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...